$ANIX

KUMAR AMIT purchased $15K of ANIX

KUMAR AMIT (Chief Executive Officer) purchased 5,000 shares of Anixa Biosciences Inc (ANIX) at $3.04 on 2026-07-10.

Original reporting
SEC EDGAR · KUMAR AMIT
Published Jul 13, 2026, 12:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 1:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The newest fact is the CEO’s disclosed open-market purchase (5,000 shares at $3.0400) and the post-transaction share count (635,812).

02

Market read

Traders may note the insider buy as a small sentiment input, but it is unlikely to drive a major repricing without accompanying fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the filing does not provide intent, timing constraints, or whether the purchase was part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-07-13, covering a purchase dated 2026-07-10.

Background

This is an SEC Form 4 insider transaction disclosure for Anixa Biosciences, Inc.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

CEO Kumar Amit filed a Form 4 open-market purchase of 5,000 shares at $3.0400 on 2026-07-10, totaling $15,200.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The article is a primary-source Form 4 showing a direct open-market purchase by the CEO, but the transaction value ($15.2k) is relatively small versus typical market-moving thresholds.

Market effects

No clear sector read-through from a single small insider purchase.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be routine and may reflect diversification or planned liquidity needs rather than a strong forward-looking signal.

Key entities

  • Anixa Biosciences Inc

    Subject of the Form 4 insider transaction disclosure.

  • Kumar Amit

    CEO and director who purchased 5,000 shares open-market.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANIXMedAI 8/10

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

$DELLLow

Silver Lake Partners IV, L.P. (Durban Egon) sold $28.0M of DELL (indirect holdings)

Silver Lake Partners IV, L.P. sold 50,728 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $552.61 ($542.78–$563.66, $28.03M total) across 21 trades on 2026-09-15. Filed jointly with Silver Lake Technology Associates IV, L.P. (Director), SLTA IV (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).